Výsledky vyhledávání

Akademický článek

PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.

Autor: Ferrarotto R; Department of Thoracic/Head and Neck Medical, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: rferrarotto@mdanderson.org., Swiecicki PL; Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA., Zandberg DP; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Baiocchi RA; Department of Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Wesolowski R; Department of Medicine, Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Rodriguez CP; Department of Medicine, University of Washington, Seattle, WA, USA., McKean M; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA., Kang H; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Monga V; Department of Medicine, Division of Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA., Nath R; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Palmisiano N; Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Babbar N; Prelude Therapeutics, Research and Development, Wilmington, DE, USA., Sun W; Prelude Therapeutics, Research and Development, Wilmington, DE, USA., Hanna GJ; Center for Head and Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.

Publikováno v: Oral oncology [Oral Oncol] 2024 Feb; Vol. 149, pp. 106634. Date of Electronic Publication: 2023 Dec 20.

Zobrazit plný text záznamu

Akademický článek

Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.

Autor: Chiu J; Queen Mary Hospital, 102 Pok Fu Lam Rd, Pok Fu Lam, Hong Kong., Su F; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, USA., Joshi M; Novartis Institutes for BioMedical Research, 250 Massachusetts Ave, Cambridge, MA, USA., Masuda N; Nagoya University Graduate School of Medicine, Building B, Furocho, Chikusa Ward, Nagoya, Japan., Ishikawa T; Tokyo Medical University Hospital, 6 Chome-7-1 Nishishinjuku, Shinjuku City, Tokyo, Japan., Aruga T; Tokyo Metropolitan Komagome Hospital, 3 Chome-18 Honkomagome, Bunkyo City, Tokyo, Japan., Zarate JP; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, USA., Babbar N; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, USA., Balbin OA; Novartis Institutes for BioMedical Research, 250 Massachusetts Ave, Cambridge, MA, USA., Yap YS; Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore, Singapore. gmsyapys@nus.edu.sg.

Publikováno v: BMC medicine [BMC Med] 2023 Aug 15; Vol. 21 (1), pp. 306. Date of Electronic Publication: 2023 Aug 15.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

232P Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC)

Autor: Yap, Y.S., Su, F., Joshi, M., Chiu, J., Masuda, N., Ito, Y., Ishikawa, T., Aruga, T., Kim, S.J., Deore, U., Babbar, N., Balbin, A.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S459-S460

Zobrazit plný text záznamu

Akademický článek

Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.

Autor: Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Su F; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Solovieff N; Novartis Pharmaceuticals Corporation, Cambridge, MA., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea., Sohn J; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Lee KS; Center for Breast Cancer, National Cancer Center, Goyang, South Korea., Campos-Gomez S; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico., Jung KH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Colleoni M; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Vázquez RV; Institut Català d'Oncologia, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain., Franke F; Hospital de Caridade de Ijuí, CACON, Ijuí, Brazil., Hurvitz S; University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA., Harbeck N; Department of Obstetrics and Gynecology, Breast Center, Ludwig-Maximilians-University Munich, Munich, Germany., Chow L; Organisation for Oncology and Translational Research, Hong Kong, China., Taran T; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Rodriguez Lorenc K; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Babbar N; Novartis Pharmaceuticals Corporation, Cambridge, MA., Tripathy D; The University of Texas MD Anderson Cancer Center, Houston, TX., Lu YS; National Taiwan University Hospital, Taipei, Taiwan.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2021 Sep 01; Vol. 5. Date of Electronic Publication: 2021 Sep 01 (Print Publication: 2021).

Zobrazit plný text záznamu

Akademický článek

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.

Autor: Prat A; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Institute of Oncology (IOB) Quiron, Barcelona, Spain., Chaudhury A; Novartis Institutes for BioMedical Research, Cambridge, MA., Solovieff N; Novartis Institutes for BioMedical Research, Cambridge, MA., Paré L; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Martinez D; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Chic N; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Martínez-Sáez O; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Brasó-Maristany F; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Lteif A; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Taran T; Novartis Pharma AG, Basel, Switzerland., Babbar N; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Su F; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 May 01; Vol. 39 (13), pp. 1458-1467. Date of Electronic Publication: 2021 Mar 26.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání